ON
🔍
← Back to feed
JapanEconomy8 days ago

Japan pharma companies turn to China for drug discovery, growth

Japanese pharmaceutical companies are increasing their investments in China, aiming to leverage the improving drug discovery capabilities of Chinese partners to identify new drug candidates. Takeda's CEO has noted that Chinese development capabilities are approaching those of the US.

Pharmaceuticals

Takeda CEO says Chinese development capabilities nearing US levels

An Astellas office in Beijing. The Japanese company is opening a new R&D facility in a Beijing industrial park. (Astellas Pharma)

Nikkei staff writers

June 13, 2026 01:56 JST

TOKYO -- Japanese pharmaceutical companies are investing more in China, the world's second-largest market, aiming to tap the rapidly improving drug discovery capabilities of Chinese partners to find promising new candidates.

Read the full article at Nikkei Asia →
Source document: Astellas Pharma

1 reports

Nikkei AsiaIndependent🔒Center
Japan pharma companies turn to China for drug discovery, growth

Japanese pharmaceutical companies are increasing their investments in China, aiming to leverage the improving drug discovery capabilities of Chinese partners to identify new drug candidates. Takeda's CEO has noted that Chinese development capabilities are approaching those of the US.

Bias read (Center): The article presents factual information about Japanese pharmaceutical companies' investments in China without overtly biased language, one-sided sourcing, or editorializing. It reports on statements from Takeda's CEO and mentions Astellas' new R&D facility in Beijing, providing a neutral overview of the situation.

Official sources cited

  • organisation Astellas Pharma

Go to the primary sources (1)

The official sources this coverage is built on. Read them directly to bypass framing.

  • organisationAstellas Pharma